Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation Study of Hypertension as a Predictor of Efficacy Bevacizumab (BV) in Combination With Chemotherapy (CT) in Metastatic Colorectal Cancer (MCC) and Metastatic Breast Cancer (MBC).

NCT01733628 is registered in ClinicalTrials.gov with Spanish Breast Cancer Research Group as lead sponsor.

NCT NCT01733628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01733628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation Study of Hypertension as a Predictor of Efficacy Bevacizumab (BV) in Combination With Chemotherapy (CT) in Metastatic Colorectal Cancer (MCC) and Metastatic Breast Cancer (MBC).
Lead sponsor
Spanish Breast Cancer Research Group
Phase
Observational
Overall status
Completed
Start date
October 23, 2012
Completion date
December 19, 2017
Enrollment
143 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, metastatic colorectal cancer